Skip to Main Content

An experimental multiple sclerosis pill the drug giant Sanofi has touted as one of its big research hopes reduced the number of lesions in a 130-patient study.

The drug, known as SAR442168, works by inhibiting a cellular signal called Bruton’s tyrosine kinase (BTK), which is also the target of the best-selling cancer drug Imbruvica. Unlike other BTK inhibitors, the Sanofi drug can get through the so-called blood-brain barrier into the brain, making it potentially useful in MS.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!